B. Riley Wealth Advisors Inc. Raises Holdings in Stryker Co. (NYSE:SYK)

B. Riley Wealth Advisors Inc. raised its position in shares of Stryker Co. (NYSE:SYKFree Report) by 1.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 29,211 shares of the medical technology company’s stock after buying an additional 428 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Stryker were worth $8,770,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Stryker by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock valued at $8,379,967,000 after acquiring an additional 143,631 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Stryker by 5.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,541,845 shares of the medical technology company’s stock worth $3,755,782,000 after purchasing an additional 642,178 shares in the last quarter. FMR LLC increased its stake in Stryker by 2.5% during the 3rd quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock worth $1,632,127,000 after buying an additional 144,208 shares during the period. Morgan Stanley boosted its position in Stryker by 4.4% in the 3rd quarter. Morgan Stanley now owns 5,315,227 shares of the medical technology company’s stock valued at $1,452,493,000 after buying an additional 223,728 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of Stryker by 0.6% during the fourth quarter. Franklin Resources Inc. now owns 4,686,440 shares of the medical technology company’s stock valued at $1,403,401,000 after acquiring an additional 29,209 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on SYK. TD Cowen increased their price target on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. UBS Group upped their price target on shares of Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. Robert W. Baird boosted their price target on Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Barclays boosted their target price on shares of Stryker from $372.00 to $376.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Finally, Needham & Company LLC raised shares of Stryker from a “hold” rating to a “buy” rating and set a $392.00 price target for the company in a report on Wednesday, May 22nd. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $370.58.

Check Out Our Latest Report on Stryker

Stryker Stock Down 0.1 %

NYSE:SYK traded down $0.26 on Monday, hitting $344.72. 815,845 shares of the company’s stock traded hands, compared to its average volume of 1,319,890. The firm has a 50-day moving average price of $336.88 and a 200-day moving average price of $330.40. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56. The company has a market cap of $131.32 billion, a PE ratio of 39.26, a price-to-earnings-growth ratio of 2.72 and a beta of 0.92. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41.

Stryker (NYSE:SYKGet Free Report) last released its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The company had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. During the same quarter in the prior year, the firm earned $2.14 EPS. The company’s revenue was up 9.7% compared to the same quarter last year. Equities analysts anticipate that Stryker Co. will post 11.95 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.93%. The ex-dividend date is Friday, June 28th. Stryker’s payout ratio is currently 36.53%.

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Featured Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.